CTNNB1 and hepatocellular carcinoma: Taken together, our results (1) demonstrate the feasibility of detection of HCC-derived mutations in the CTNNB1 gene in urine cfDNA, (2) provide evidence of association between the presence of CTNNB1 mutations in urine and the presence of minimum residual disease or HCC recurrence, and (3) warrant a further study for the application of urinary CTNNB1 mutation analysis in HCC precision medicine/disease management.